Silve Vicent leads the Oncogenes and Effector Targets (OnTARGET) group at Center for Applied Medical Research (CIMA) (Pamplona, SPAIN) and is Associated Lecturer at the University of Navarra. His studies have centered around two main topics in the RAS field: 1) to develop integrative gene expression analysis to identify central KRAS effectors across tumors, and 2) to implement integrative approaches to uncover novel therapeutic strategies for the treatment of mutant KRAS tumors. His group has made significant contributions to the field published in top journals (Macaya et al, Nat Comms, 2023; Entrialgo-Cadierno et al, Mol Cancer, 2023; Erice et al, Clin Cancer Res, 2023; Vallejo et al, J Hepatol, 2021; Valencia et al, JCI, 2020; Roman et al, Cancer Res, 2019; Vallejo et al, Nat Comms, 2017).
He is member of the Spanish Cancer Network (CIBERONC), the Spanish Alliance on Pancreatic Cancer Research (ALIPANC), the European Network for the Study of Cholangiocarcinoma (ENSCCA) and Precision Biliary Tract Network, and the Health Research Institute of Navarra (IdISNa).
Tuesday, 17 June 2025
Time |
Session |
|
15:20
16:55
|
-
Detection of Cancer with Liquid Biopsy
-
Towards multi-modal liquid biopsies
-
Proffered Paper: Unravelling Principles of Adaptive Chemoresistance through Dynamic Transcriptional Patterns in Individual Breast Cancer Patients
EACR25-0255
-
Proffered Paper: KRAS pharmacological blockade elicits tumoral homologous recombination deficiency exploitable with PARP inhibitors
EACR25-0812
-
A DNA methylation atlas of normal human cell types
Auditorium VI+VII
|